Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Clodronate Liposomes: Macrophage Depletion Workflows
2026-09-10
Clodronate Liposomes provide a practical way to test whether macrophages are required for injury, repair, or drug response in vivo. This guide connects phagocytosis-mediated delivery and apoptosis induction in macrophages with controls, tissue-specific workflows, single-cell readouts, and troubleshooting for liver ischemia-reperfusion research.
-
GPR35–KLF5 Control of Epithelial Repair
2026-09-09
The reference study identifies a tryptophan–kynurenine–kynurenic acid sensing system in which GPR35 detects mucosal damage and signals through KLF5 and PI3K–AKT–mTOR to coordinate intestinal epithelial proliferation and migration. These findings provide a mechanistic framework for interpreting repair, rather than inflammation alone, in ulcerative colitis research and DSS-based intestinal injury models.
-
Liproxstatin-1 HCl Ferroptosis Workflow
2026-09-09
Liproxstatin-1 HCl provides nanomolar ferroptosis rescue for cell-based lipid peroxidation studies and translational injury models. This workflow shows how to improve compound handling, distinguish ferroptosis from apoptosis, and connect mitochondrial calcium signaling to practical assay design.
-
SU 5402: RTK Inhibition for Signaling Studies
2026-09-08
SU 5402 is a research inhibitor of VEGFR2, FGFR1, PDGFRβ, and EGFR signaling, with strongest reported activity against VEGFR2 and FGFR1. Its profile supports receptor tyrosine kinase studies in cancer biology and multiple myeloma research, but it does not by itself establish antiviral activity in human neuron models.
-
Cy5-UTP: From RNA Labeling to LNP Insight
2026-09-08
Cy5-UTP can connect RNA probe synthesis with more rigorous mRNA delivery analytics. This thought-leadership guide examines how direct fluorescent labeling, simulation-guided lipid nanoparticle size control, and translational assay design can work together—while clearly separating established product utility from future LNP applications.
-
Naftifine HCl in Antifungal Research Workflows
2026-09-07
Build more reproducible sterol-biosynthesis and fungal membrane assays with Naftifine HCl, from solvent preparation through orthogonal validation. The workflow also clarifies how this allylamine antifungal agent can inform mycology studies without being misapplied as a probe of the WNT5a/GSK3/β-catenin pathway.
-
Lovastatin Workflows for HMG-CoA Reductase Studies
2026-09-07
Lovastatin enables controlled interrogation of cholesterol and isoprenoid depletion across cancer, fibroblast, mesangial-cell, and macrophage assays. This practical guide connects dose design, formulation control, orthogonal readouts, and a carefully bounded plant-development comparison.
-
SOD Activity Assay: Reading Redox Biology Clearly
2026-09-05
The Superoxide Dismutase Activity Assay Kit enables a rapid colorimetric SOD Activity Assay based on WST-1 reduction. This guide explains what the signal means, how it differs from hydrogen peroxide assays, and how to build a defensible oxidative stress workflow.
-
Self-Assembling EVMPs for Extrahepatic mRNA Delivery
2026-09-04
The reference study presents a bottom-up enveloped virus-mimicking particle (EVMP) that combines a computationally engineered self-assembling peptide with tissue-selective phospholipid envelopes for mRNA delivery beyond the liver. Optimized particles produced substantial lung-cell transfection and suppressed metastatic lung tumors with IL-12 mRNA, while the modular design offers a framework for improving tissue targeting and repeat dosing.
-
U0126: Selective MEK1/2 Inhibitor Guide
2026-09-04
U0126 is a non-ATP-competitive MEK1/2 inhibitor that suppresses ERK1/2 phosphorylation and supports mechanistic studies of MAPK signaling. Its defined nanomolar kinase benchmarks, cell permeability, and reported effects on autophagy and mitophagy make it useful across cancer biology research and neurobiology, subject to assay-specific validation.
-
Diminazene Aceturate: Applied Research Workflows
2026-09-03
Diminazene Aceturate supports two distinct research paths: trypanocidal experiments in parasite systems and pharmacological ACE2 activation studies linked to cardiac mitochondrial biology. This practical guide covers formulation, assay design, controls, optimization, and the limitations of translating findings between these domains.
-
Naftifine HCl for Antifungal Assay Design
2026-09-03
Naftifine HCl provides a practical, mechanism-led tool for sterol-biosynthesis studies, fungal growth assays, and orthogonal control design. This guide connects its allylamine antifungal activity with disciplined workflows inspired by WNT5a/GSK3/β-catenin research while clearly separating validated antifungal applications from exploratory muscle-cell experiments.
-
Z-YVAD-FMK in HOXC8-Driven Pyroptosis Research
2026-09-02
Explore how the caspase-1 inhibitor Z-YVAD-FMK can clarify the HOXC8–CASP1–GSDMD axis in lung cancer. This mechanistic guide explains assay design, controls, dosing logic, and the limits of interpreting pyroptosis inhibition.
-
EdU Imaging Kits (HF594) for Resistance Studies
2026-09-02
EdU Imaging Kits (HF594) transform DNA synthesis measurement into a decision-ready readout for gefitinib-resistant adenocarcinoma models. This article explains how click chemistry, dual-platform imaging, and careful endpoint interpretation can strengthen studies of PI3K–AKT–ERK blockade and nanomedicine.
-
Viral RIPK3 Degradation and Inflammation
2026-09-01
Liu and colleagues identified a conserved orthopoxvirus factor that recruits host SCF machinery to promote RIPK3 ubiquitination and proteasomal degradation. Their genetic, biochemical, virological, and mouse experiments show that this viral inducer of RIPK3 degradation reshapes necroptosis, inflammation, viral replication, and pathogen–host adaptation.